$ARQQ

Willcocks Patrick sold $13K of ARQQ

Willcocks Patrick (General Counsel) sold 555 shares of Arqit Quantum Inc. (ARQQ) at $24.19 on 2026-10-06.

Original reporting
SEC EDGAR · Willcocks Patrick
Published Oct 8, 2026, 10:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQQ
Bearish
medium confidence
Mentioned
$ARQQ
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQQBearishLow
01

Why it matters

The modest insider sell provides a new data point but is unlikely to move the stock significantly.

02

Market read

A routine insider sale of modest size with limited market impact.

03

What to watch

The sale represents only 0.5% of the insider's holdings, limiting its significance.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing shows Arqit Quantum Inc. insider Willcocks Patrick sold 555 shares at $24.19 each, totaling $13,426, leaving 11,209 shares owned.

Company-level read

Ticker impact

$ARQQBearishMedium confidence
Context

General Counsel Willcocks Patrick sold 555 shares of Arqit Quantum for $13,426, reducing his stake to 11,209 shares.

Expected impact

potential slight pressure from insider sell

Evidence & confidence

The transaction size is modest but represents a sell by a senior officer, which can be interpreted as a lack of confidence.

Market effects

Minimal impact on the quantum technology sector.

None

Low

Counterpoint

The small sale may simply be portfolio rebalancing and not a negative signal.

Key entities

  • Arqit Quantum Inc.

    Quantum technology firm listed on Nasdaq under ticker ARQQ.

  • Willcocks Patrick

    General Counsel of Arqit Quantum, reporting insider transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QNTMedAI 9/10

Quantum Computing Shares Sink Ahead Of Blockbuster Quantinuum IPO

Quantinuum (QNT) shares fell Wednesday as the Honeywell-backed firm neared its Nasdaq debut, with pricing set for June 3 and first trading expected June 4. The company plans to sell 26.5 million shares at $53–$55 to raise about $1.46 billion, valuing it at up to $14.3 billion, according to the report. Other quantum stocks also declined.

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).